Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

July 24, 2024 04:05 PM EDT | By EODHD

Google News:

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024 — Image source: Kalkine Media

Recent News

From $80 and a Basement Apartment to Entrepreneur of the Year at the 2...

SpecFive Unveils Voyager: A Solar-Powered, Vehicle-Mounted Meshtastic...

Zeke Wilson Launches Crowdfunding Campaign for 'The Eighth Round'

Industry expert to appear as panelist at wireless, AI, telecom confere...

Company to host conference call and webcast on Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time SAN DIEGO, July 24, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq:ACAD) today announced that it will report second quarter financial results on Tuesday, August 6, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 6, 2024, at 4:30 p.m.

Eastern Time to discuss financial results and operations. The conference call will be available on Acadia’s website, Acadia.com under the investors section and will be archived there until September 6, 2024. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life.

For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter. View source version on businesswire.com: https://www.businesswire.com/news/home/20240724261503/en/ Contacts Investor Contact: Acadia Pharmaceuticals Inc.

Al Kildani (858) 261-2872 [email protected] Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950 [email protected] View comments()

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media Incorporated (“Kalkine Media, we or us”), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used in the Content are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

View All

News

Trending Topics

Related Articles

Sponsored Articles

1

2

3

4

5

Investing Ideas

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20